Ticker: NASDAQ: QUCY (formerly MYNZ) | Sector: Molecular Diagnostics / Biotech | Market Cap: Micro-cap
Disclosure: This article is for informational purposes only and does not constitute investment advice. The author holds no position in QUCY/MYNZ. Small-cap biotech stocks carry extreme risk. Always conduct your own due diligence.
There’s an interesting story buried inside what used to be called Mainz Biomed — a company developing a blood-based pancreatic cancer screening test that in a preliminary study achieved 100% sensitivity and 95% specificity. Those numbers are remarkable in a disease that currently has no reliable early-detection option for average-risk populations.
But there’s a plot twist: as of March 12, 2026, Mainz Biomed no longer trades as MYNZ. The company changed its ticker to QUCY and is rebranding as Quantum Cyber N.V. — pivoting toward quantum computing and cybersecurity.
So is this a dead story? Not quite. The AACR catalyst in April is still coming. The pancreatic cancer data is still the most scientifically interesting thing about this company. And the strategic chaos around the pivot creates exactly the kind of information asymmetry where small-cap investors can find an edge — if they understand what they’re actually betting on.
What Mainz Biomed Originally Was
Founded in 2008 in Mainz, Germany and listed on NASDAQ in November 2021, Mainz Biomed built its initial business around ColoAlert®, a DNA-based colorectal cancer stool test designed to compete in the European market against Exact Sciences’ Cologuard. The company has about 26 employees and generated just under $900,000 in revenue in 2024 — against operating losses of $21.65 million. This is clearly a pre-commercial research-stage company, not a cash-flowing business.
ColoAlert found modest traction in Europe, receiving regulatory clearance in the UK (MHRA) and Switzerland (Swissmedic), and signed distribution partnerships in South America and collaborations with German health insurance networks. The company also launched eAArly DETECT 2, a 2,000-patient US feasibility study for its next-generation colorectal cancer test, and maintains a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of its testing platform.
But the real story — and the one that put MYNZ on investors’ radar — is the pancreatic cancer program.
The Pancreatic Cancer Problem: A $10B Unmet Need
Pancreatic cancer is one of medicine’s most stubborn problems. The five-year survival rate is roughly 12-13% overall — but jumps to 44% when caught at Stage I. The catch is that only about 10% of pancreatic cancers are diagnosed early. Most patients are diagnosed at Stage III or IV, when surgical resection is no longer possible and systemic chemotherapy offers limited benefit.
Why does this happen? There is currently no routine, non-invasive screening test for pancreatic cancer in average-risk individuals. The existing blood marker CA 19-9 has poor sensitivity for early-stage disease and even worse specificity — it’s elevated in benign conditions including pancreatitis, cholangitis, and liver disease. Endoscopic ultrasound and MRI are reserved for high-risk patients (those with genetic mutations like BRCA2 or PALB2, or family history), not the general population.
The global pancreatic cancer diagnostics market is expected to reach over $3 billion by 2030, with non-invasive early detection representing an enormous commercial prize. Multiple players — including Grail (Galleri), Guardant Health (Shield), and Exact Sciences — are racing to develop liquid biopsy solutions. But for pancreatic cancer specifically, a validated blood-based screening test remains elusive.
PancAlert: The Science Behind the 100% Sensitivity Claim
In March 2025, Mainz Biomed signed a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA biomarkers for pancreatic cancer detection. Liquid used their proprietary EMERGE platform to analyze blood samples from 285 subjects (35 with pancreatic cancer) and identified a panel of clinically relevant mRNA biomarkers that achieved 95% sensitivity and 98% specificity in the discovery cohort.
Mainz Biomed then ran its own feasibility study to verify and refine those results. The October 2025 topline readout was striking:
Researchers evaluated 18 licensed biomarkers across multiple candidate panels to streamline assay complexity. The leading panel achieved 100% sensitivity and 95% specificity, successfully distinguishing pancreatic cancer patients from healthy controls in a 30-subject cohort, reflecting different stages of the disease as well as precursors.
Critically, the test is designed not just to detect PDAC (pancreatic ductal adenocarcinoma) — the most common and deadly form — but also to differentiate it from IPMNs (Intraductal Papillary Mucinous Neoplasms), benign cyst-like lesions in the pancreas that are frequently over-treated because current imaging can’t reliably predict which ones will become malignant. A test that can correctly classify IPMNs would have significant clinical and commercial value beyond simple cancer detection.
The test uses real-time PCR multiplex detection of mRNA biomarkers in blood, combined with an AI-assisted modeling approach. Importantly, it’s blood-based — not stool-based like PancAlert’s predecessor — which dramatically improves patient adoption potential.
The company also received public funding from the ISB (Investitions- und Strukturbank Rheinland-Pfalz), the German state development bank, covering up to 50% of the project’s total costs. Government scientific validation of this kind rarely goes to projects without real scientific merit.
The AACR Catalyst: April 17-22, San Diego
The American Association for Cancer Research (AACR) Annual Meeting is one of the most prestigious oncology conferences in the world. Mainz Biomed announced in January 2026 that it will present verification study results at the event, which runs April 17-22, 2026 in San Diego.
The abstract describes:
First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented.
The company will present results from a 30-subject cohort evaluating its “compact proprietary combination of blood-derived mRNA biomarkers and an AI-assisted modeling approach designed to differentiate PDAC from benign conditions including IPMNs.”
AACR presentations can be significant stock-moving events, particularly for micro-cap biotechs presenting cancer data in front of academic and industry leaders. If the verification study confirms the 100% sensitivity figure from the feasibility readout, it would represent meaningful scientific de-risking. A data disappointment, on the other hand, could erase any pre-AACR run.
The company is also presenting at Digestive Disease Week (DDW) 2026 in Chicago, with the poster titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS” — doubling down on the dual-use angle.
The Plot Twist: Now Trading as QUCY
Here’s where it gets complicated, and where investors need to read carefully.
In February 2026, Mainz Biomed announced a $6 million private placement with investor David Lazar, structured as convertible non-redeemable preferred stock in two $3M tranches. With the financing came a strategic pivot: the company would wind down its German subsidiary, sell the ColoAlert colorectal cancer assets, and concentrate entirely on the U.S. pancreatic cancer detection program.
Then, in March 2026, a second shoe dropped. Mainz Biomed announced it was appointing Robert Liscouski — the first Assistant Secretary for Infrastructure Protection at the U.S. Department of Homeland Security, and co-founder/former CEO of Quantum Computing Inc. (QUBT) — as Chairman of the Board. Simultaneously, the company announced it would rename itself Quantum Cyber N.V. and trade under the new ticker QUCY, with plans to shift toward quantum computing and cybersecurity offerings.
As of March 12, 2026, MYNZ is gone. QUCY is the new ticker.
What does this mean for the pancreatic cancer thesis? The company says it is “continuing to make progress” on the pancreatic screening program, and the AACR presentation is still on schedule. But the strategic direction of the business is now explicitly toward an entirely different sector. The leadership team now has a quantum computing pedigree, not a diagnostics one.
Competitive Landscape
The liquid biopsy space for cancer early detection is intensely competitive:
- Grail (GRAL) — Galleri multi-cancer early detection test, backed by billions in capital and a large validation dataset (Pathfinder study). Multi-cancer, but pancreatic sensitivity in Galleri’s trials has been modest for early stage.
- Guardant Health (GH) — Shield test (CRC-focused), also exploring multi-cancer. Well-capitalized.
- Exact Sciences (EXAS) — Cologuard dominates the stool-based CRC market. Acquired Thrive Earlier Detection for multi-cancer.
- CA 19-9 — The incumbent pancreatic cancer marker. Low sensitivity for early stage, poor specificity. No competitive moat for whoever can replace it.
Mainz Biomed’s (now QUCY’s) differentiation is the mRNA biomarker approach (rather than circulating tumor DNA) and the specificity for PDAC vs. IPMN differentiation — a clinical gap that larger players haven’t addressed head-on. Whether the company retains or monetizes this intellectual property in its new quantum computing guise is the central unanswered question.
The Investment Case: Risk/Reward in Plain Language
What’s compelling:
- 100% sensitivity in the feasibility study is an extraordinary preliminary result if it holds in larger validation
- AACR April 2026 is a near-term, date-certain catalyst with binary potential
- Thermo Fisher partnership suggests scientific credibility
- German government funding (50% cost coverage) provides external validation
- IPMN differentiation is a unique clinical angle no major competitor has emphasized
- Tiny float and micro-cap size means a data catalyst could move the stock significantly
What’s deeply concerning:
- Only 30 subjects in the feasibility study — far too small to draw conclusions about population-level performance
- The company just pivoted its entire business model to quantum computing and cybersecurity
- 2024 revenue: $894K against $21.65M in operating losses — pre-commercial, burning cash
- Convertible preferred financing is inherently dilutive
- Winding down the German subsidiary and selling ColoAlert removes the only revenue-generating asset
- No clear articulation of how the pancreatic cancer assets fit in the “Quantum Cyber” strategy
- New leadership has quantum computing background, not cancer diagnostics experience
- Even if AACR data is positive, full FDA approval for a new cancer screening test is a 5-10 year process
Bottom line: Before the pivot announcement, MYNZ was a speculative binary: compelling early science, enormous unmet need, AACR catalyst, serious funding/dilution risks. After the pivot to QUCY, it’s something harder to categorize — a company with a promising cancer diagnostic asset being steered by quantum computing investors toward an entirely different direction.
The AACR catalyst is still real. The science is still interesting. But investors need to understand they are now buying a company that may sell, spin out, or deprioritize the very asset they came for.
Key Dates to Watch
- April 15, 2026 — Expected closing of second $3M tranche of private placement
- April 17–22, 2026 — AACR Annual Meeting, San Diego — PancAlert verification study presentation
- April 2026 — Extraordinary General Meeting — formal company name change to Quantum Cyber N.V.
- TBD 2026 — Potential ColoAlert asset sale announcement
- TBD 2026 — DDW 2026, Chicago — poster presentation on mRNA biomarkers
Final Take
The MYNZ/QUCY story is a rare case where the most interesting scientific asset and the most disruptive corporate event are happening simultaneously. The 100% sensitivity claim for a blood-based pancreatic cancer test — if confirmed at AACR — would be one of the more significant early-detection results in oncology. But the company presenting that data is now run by quantum computing executives who have just renamed the business “Quantum Cyber.”
For investors willing to tolerate extreme uncertainty, the April AACR window offers a specific, time-bounded event to trade around. The underlying science justifies watching closely. But position sizing should reflect the reality that this is a company with under $1M in revenue, $21M in annual losses, a leadership team from an entirely different industry, and a business model undergoing complete reconstruction.
Speculative. Volatile. Genuinely interesting. That’s the QUCY thesis in three sentences.
Sources: Mainz Biomed press releases (Jan–Mar 2026), SEC filings via mainzbiomed.com, StockAnalysis.com financial data. All clinical data as reported by the company; independent verification of study results not possible at this stage. This article was published March 13, 2026 and reflects information available as of this date.